{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:12:47Z","timestamp":1792300367313,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.05.026","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T07:14:39Z","timestamp":1750490079000},"page":"1078-1086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment"],"prefix":"10.1016","volume":"8","author":[{"given":"Ugo Giovanni","family":"Falagario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bj\u00f6rnebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abbadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Valdman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorgerdur","family":"Palsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00f6nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ash","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Akre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.05.026_b0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.euo.2025.05.026_b0010","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM198710083171501","article-title":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","volume":"317","author":"Stamey","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.05.026_b0015","unstructured":"Mottet N, van den Bergh RCN, Briers E, et al. EAU - ESTRO - ESUR - SIOG guidelines on prostate cancer 2020. European Association of Urology Guidelines 2020 edition. Presented at the EAU Annual Congress Amsterdam 2020. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2020."},{"key":"10.1016\/j.euo.2025.05.026_b0020","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.05.026_b0025","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.05.026_b0030","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2011.02.026","article-title":"Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence","volume":"59","author":"Boorjian","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.026_b0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2019.06.004","article-title":"Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel recommendations","volume":"6","author":"Van den Broeck","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.05.026_b0040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.026_b0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2024.04.034","article-title":"Risk stratification of patients with recurrence after primary treatment for prostate cancer: a systematic review","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.026_b0050","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the European Association of Urology Biochemical Recurrence Risk Groups to predict metastasis and mortality after radical prostatectomy in a European cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.026_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.05.026_b0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2012.10.001","article-title":"Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003\u20132011","volume":"63","author":"Nordstr\u00f6m","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.026_b0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/21681805.2020.1739139","article-title":"Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden","volume":"54","author":"Aly","year":"2020","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2025.05.026_b0070","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.euo.2025.05.026_b0075","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1016\/j.clon.2023.09.012","volume":"35","author":"Subiela","year":"2023","journal-title":"Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.026_b0080","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.026_b0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2021.06.017","article-title":"Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na\u00efve prostate cancer","volume":"157","author":"Spetsieris","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.05.026_b0090","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.24.00279","article-title":"Metastasis-free survival versus treatment-free survival in biochemically recurrent prostate cancer: the EMBARK trial","volume":"42","author":"Einstein","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.026_b0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/CCO.0000000000001030","article-title":"Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients","volume":"36","author":"Einstein","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.euo.2025.05.026_b0100","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jamaoncol.2024.3074","article-title":"Olaparib without androgen deprivation for high-risk biochemically recurrent prostate cancer following prostatectomy: a nonrandomized controlled trial","volume":"10","author":"Marshall","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.05.026_b0105","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35612","article-title":"Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: consensus recommendations from the US Prostate Cancer Conference 2024","volume":"131","author":"Bryce","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.05.026_b0110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41391-023-00711-0","article-title":"Application of next-generation imaging in biochemically recurrent prostate cancer","volume":"27","author":"Moul","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.05.026_b0115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500166X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112500166X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:26:31Z","timestamp":1758079591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112500166X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S258893112500166X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.026","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}